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OBJECTIVE: This study was conducted to investigate factors associated with thrombocytopenia in a large cohort
of patients with leptospirosis in an endemic area.
METHODS: This retrospective study included 374 consecutive patients with leptospirosis who were admitted to
tertiary hospitals in Fortaleza, Brazil. All patients had a diagnosis of severe leptospirosis (Weil’s disease). Acute
kidney injury was defined according to the RIFLE criteria. Thrombocytopenia was defined as a platelet count
,100,000/mm3.
RESULTS: A total of 374 patients were included, with a mean age of 36.1¡15.5 years, and 83.4% were male.
Thrombocytopenia was present at the time of hospital admission in 200 cases (53.5%), and it developed during
the hospital stay in 150 cases (40.3%). The patients with thrombocytopenia had higher frequencies of
dehydration (53% vs. 35.3%, p=0.001), epistaxis (5.7% vs. 0.8%, p=0.033), hematemesis (13% vs. 4.6%,
p=0.006), myalgia (91.5% vs. 84.5%, p=0.038), hematuria (54.8% vs. 37.6%, p=0.011), metabolic acidosis (18%
vs. 9.2%, p=0.016) and hypoalbuminemia (17.8% vs. 7.5%, p=0.005). The independent risk factors associated
with thrombocytopenia during the hospital stay were lengthy disease (OR: 1.2, p=0.001) and acute kidney
injury (OR: 6.6, p=0.004). Mortality was not associated with thrombocytopenia at admission (12.5% vs. 12.6%,
p=1.000) or during the hospital stay (12.6% vs. 11.3%, p=0.748).
CONCLUSIONS: Thrombocytopenia is a frequent complication in leptospirosis, and this condition was present in
more than half of patients at the time of hospital admission. Lengthy disease and acute kidney injury are risk
factors for thrombocytopenia. There was no significant association between thrombocytopenia and mortality.
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& INTRODUCTION
Leptospirosis is an infectious disease caused by the
pathogenic spirochete Leptospira interrogans, which has a
worldwide distribution (1-3). There is a large range of
clinical manifestations in leptospirosis, and infected people
can present with asymptomatic illness, self-limited systemic
infection or severe and potentially fatal disease (1-5).
Symptomatic disease begins suddenly, with headache,
fever, malaise, myalgia, conjunctival suffusion and transient
rash (1). The severe form is characterized by jaundice, acute
kidney injury (AKI) and hemorrhage, known asWeil’s disease,
and is mainly caused by the serovars Icterohaemorrhagiae,
Copenhageni and Lai. There are also severe forms of the disease
that occur without jaundice or renal failure, such as hemor-
rhagic pneumonitis (1,2).
Hematological manifestations are common in leptospiro-
sis and are usually manifested as thrombocytopenia (6-8).
Thrombocytopenia is often observed in connection with
hemorrhagic pneumopathy and is a significant predictor of
the development of acute respiratory failure, which is
currently the main cause of death in this disease (6,7,9).
The aim of this study was to investigate the factors
associated with thrombocytopenia in a large cohort of
patients with severe leptospirosis in an endemic area.
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& PATIENTS AND METHODS
We examined a retrospective cohort of 374 consecutive
patients admitted to tertiary hospitals in Fortaleza, north-
eastern Brazil. All patients had a diagnosis of leptospirosis
confirmed by a microscopic agglutination test (MAT), with
titers equal to or higher than 15800. Serological testing was
performed at least 7 days after admission, and patients with
titers lower than 15800 were excluded. Patients with
negative serologies or other comorbidities, such as hyper-
tension, diabetes and autoimmune diseases, were not
included. The protocol of this study was approved by the
ethics committees of both institutions.
Demographic characteristics, such as age, gender, the
time between the onset of the initial symptoms and hospital
admission and the length of hospital stay, were recorded.
The clinical investigation included a record of all clinical
signs and symptoms presented by each patient at hospital
admission and during the hospital stay. Hemorrhagic
phenomena, such as gastrointestinal hemorrhage, hemop-
tysis or blood-tinged sputum, hematuria and epistaxis, were
recorded at admission and during hospitalization.
Laboratory data collected during the hospital stay included
an assessment of serum urea, creatinine, sodium, potassium,
bilirubin, aspartate aminotransaminase (AST), alanine ami-
notransaminase (ALT), creatine kinase and lactate dehy-
drogenase levels; the total blood count; and the prothrombin
time (PT).
Respiratory failure was defined as a need for mechanical
ventilation. AKI was defined according to the RIFLE criteria
(10). Thrombocytopenia was defined as a platelet count
,100,000/mm3, and severe thrombocytopenia was defined
as a count ,50,000/mm3. The occurrence of metabolic acido-
sis was diagnosed at a pH ,7.35 and HCO3 ,20 mEq/L.
Oliguria was defined as a urine volume ,400 mL/day after
24 h of effective hydration. Hypotension was defined as a
mean arterial blood pressure (MAP) ,60 mmHg, and
therapy with vasoactive drugs was initiated when the MAP
remained,60 mmHg. The systolic blood pressure (SBP) and
diastolic blood pressure (DBP) at admission were also
analyzed. Dialysis was indicated in those patients who
remained oliguric after effective hydration, in those cases in
which uremia was associated with hemorrhagic or severe
respiratory failure and in those patients with hyperkalemia
or metabolic acidosis that was refractory to clinical treatment.
The use of antibiotic therapy in the later phase of leptos-
pirosis is still controversial, but penicillin G was adminis-
tered to several patients, at the discretion of the assistant, at a
dosage of 8 million units/day in the first 7-10 days after the
patients were admitted.
& RESULTS
The patients were divided into two groups according to
their platelet levels (with thrombocytopenia vs. without
thrombocytopenia). A comparison of clinical and labora-
tory characteristics was performed to investigate the
differences between the two groups. All data were
analyzed with the program SPSS ver. 10.0 (Chicago, IL,
USA). The comparison of parameters was performed with
a Student’s t-test and Fisher’s exact test. The Mann-
Whitney U-test was used for the parameters with a non-
normal distribution. A logistic regression model was used
for the quantitative variables. Adjusted odds ratios (ORs)
and 95% confidence intervals (CIs) were calculated. A
multivariate logistic regression was performed to analyze
the possible risk factors associated with thrombocytopenia
and death. The factors included in the multivariate model
were those that showed significance (p,0.05) in the
univariate analysis.
The patients’ mean age was 36.1¡15.5 years, and 312
(83.4%) were male. The time between the onset of symptoms
and hospital admission was 4.4¡3.8 days for patients with
thrombocytopenia and 5.9¡4.8 days for patients without
thrombocytopenia (p= 0.001). The average length of hospital
stay was 10.3¡6.9 days for patients with thrombocytopenia
and 9.3¡6.2 days for patients without thrombocytopenia
(p= 0.190).
The main signs and symptoms presented at admission
were fever (96%), myalgia (88.2%), jaundice (78.9%), calf
pain (74.2%), headache (72.2%), vomiting (68.2%), asthenia
(55.8%), anorexia (50.7%), chills (49.2%), coluria (47.8%),
hematuria (47.1%), abdominal pain (46.6%), dehydration
(44.8%), diarrhea (41.2%), hepatomegaly (28.9%) and oli-
guria (21.2%).
Thrombocytopenia was present at hospital admission in
200 cases (53.5%), and 150 (40.3%) patients developed this
condition during their hospital stay. Severe thrombocyto-
penia (,50,000/mm3) was found in 107 patients (29.3%).
Patients with thrombocytopenia at admission had higher
frequencies of dehydration (53% vs. 35.3%, p= 0.001),
epistaxis (5.7% vs. 0.8%, p= 0.033), hematemesis (13% vs.
4.6%, p= 0.006), myalgia (91.5% vs. 84.5%, p= 0.038),
hematuria (54.8% vs. 37.6%, p= 0.011), metabolic acidosis
(18% vs. 9.2%, p= 0.016) and hypoalbuminemia (17.8% vs.
7.5%, p= 0.005). The frequency of oliguria was not higher in
patients with thrombocytopenia (23.1% vs. 19.0%, p=0.374).
Penicillin use had a tendency to be more frequent in patients
without thrombocytopenia at admission (42.6% vs. 32%,
p= 0.07). These data are summarized in Table 1.
Regarding the laboratory data, patients with thrombocy-
topenia at admission presented with hypokalemia (3.2¡0.6
vs. 3.5¡0.6 mEq/L, p,0.0001), hypoalbuminemia (2.9¡0.6
vs. 3.2¡0.6 g/dL, p= 0.067), low hemoglobin levels
(10.7¡2.0 vs. 11.2¡2.1 g/dL, p= 0.021) and high total
bilirubin levels (12.3¡11.0 vs. 7.5¡9.1 mg/dL, p= 0.001)
significantly more often than did patients with normal
platelet levels (Table 2).
The multivariate analysis showed that hypokalemia (OR:
0.7, p= 0.02), dehydration (OR: 2.1, p= 0.006) and metabolic
acidosis (OR: 2.3, p= 0.03) were independent risk factors for
thrombocytopenia at admission (Table 3). Lengthy disease
(OR: 1.2, p= 0.001) and the presence of AKI (OR: 6.6,
p= 0.004) were independent risk factors for thrombocytope-
nia during the hospital stay (Table 4).
Death occurred in 22 patients (12.5%) without thrombo-
cytopenia and 25 patients (12.6%) with thrombocytopenia at
admission. Mortality was not associated with the presence
of thrombocytopenia at hospital admission (12.5% vs. 12.6%,
p= 1.000) or during the hospital stay (12.6% vs. 11.3%,
p= 0.748).
Low DBP (OR: 0.9, p= 0.02), advanced age (OR: 1.0,
p= 0.001) and oliguria (OR: 5.4, p= 0.006) were independent
risk factors for death (Table 5).
& DISCUSSION
Hemorrhagic complications contribute to mortality in
leptospirosis. Recent studies have shown a direct association
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between thrombocytopenia and the occurrence of bleeding
manifestations (7). In the present study, we evaluated a large
number of patients with leptospirosis-associated thrombocy-
topenia.
Most studies on leptospirosis have focused on AKI and
pulmonary complications. After several outbreaks of pul-
monary hemorrhage in association with leptospirosis,
attention has shifted to understanding the mechanism of
bleeding diathesis in these patients. Initially, thrombocyto-
penia in leptospirosis was thought to be mild and rare.
However, certain reviews have reported a higher prevalence
(12,13). There are several hypotheses about the possible
mechanism of this complication: 1) the presence of
disseminated intravascular coagulation (12); 2) the partici-
pation of cytotoxins (13); and 3) the direct complication of
vasculitis, triggered by the Leptospira (14). Further studies
are needed to establish the actual pathophysiology of this
complication.
The independent risk factors for thrombocytopenia were
dehydration, metabolic acidosis and low potassium levels at
admission. Low serum potassium was a protective factor
against thrombocytopenia, i.e., hyperkalemia is associated
with thrombocytopenia. This phenomenon may be due to
oliguric AKI and metabolic acidosis because there is no
cause-effect relationship between serum potassium and the
occurrence of thrombocytopenia. Dehydration and meta-
bolic acidosis are systemic manifestations of leptospirosis
that are associated with thrombocytopenia. Hemorrhagic
manifestations were more frequent in patients in the
thrombocytopenia group. Thrombocytopenia was also
associated with poor laboratory findings, such as hypoal-
buminemia, lower hemoglobin levels and higher AST and
total bilirubin levels. However, this condition did not
translate into a worse prognosis. In contrast to our study,
Spichler et al. (14) reported that elevated creatinine
(.3 mg/dL; OR: 4.2) and total bilirubin (.6 mg/dL; OR:
2.2) levels were associated with a lethal outcome. Turgut
et al. (15) showed that there was an inverse correlation
between ALT/AST levels and thrombocyte counts (r =
–0.360; p= 0.016) and that, consistent with our data, there
was no statistically significant correlation between bilirubin
levels and thrombocytopenia. Certain researchers have
reported that a high serum potassium level at hospital
admission was an independent risk factor for mortality
(16,17).
In our study, the overall mortality rate was 12.5%, which
is comparable with the rate in other studies (17-23). This
large range may be due to the variable severity of the
clinical picture, which is partly due to differences between
Leptospira strains and the absence of standards for the
Table 1 - Comparison of the demographics and clinical manifestations of leptospirosis patients with and without
thrombocytopenia at admission.
Thrombocytopenia No thrombocytopenia p-value
(N = 200) (N = 174)
Age 36.4¡16.3 36.7¡15.0 0.624
(9-82 years) (9-84 years)
Gender
Male 168 (84.0%) 144 (82.8%) 0.781
Female 32 (16.0%) 30 (17.2%)
Length of hospital stay 10.3¡6.9 9.3¡6.2 0.190
Signs and symptoms
Crackles 33 (16.5%) 28 (16.1%) 1.000
Coluria 56 (45.5%) 64 (50%) 0.528
Dehydration 106 (53.0%) 61 (35.3%) 0.001
Diarrhea 79 (39.5%) 75 (43.1%) 0.528
Dyspnea 23 (11.7%) 16 (9.2%) 0.499
Epistaxis 7 (5.7%) 1 (0.8%) 0.033
Fever 194 (97.0%) 165 (94.8%) 0.304
Headache 147 (73.5%) 123 (70.7%) 0.565
Hematemesis 26 (13.0%) 8 (4.6%) 0.006
Hematuria 69 (54.8%) 38 (37.6%) 0.011
Hepatomegaly 65 (32.5%) 43 (24.7%) 0.110
Hypotension 13 (10.6%) 14 (10.9%) 1.000
Jaundice 164 (82.0%) 131 (75.3%) 0.128
Myalgia 183 (91.5%) 147 (84.5%) 0.038
Tachypnea 49 (24.5%) 32 (18.4%) 0.167
Vomiting 144 (72.0%) 111 (63.8%) 0.096
Anorexia 80 (53.7%) 65 (47.4%) 0.344
Asthenia 66 (53.7%) 74 (57.8%) 0.527
Oliguria 33 (19.0%) 46 (23.1%) 0.374
Calf pain 106 (78.5%) 78 (69.0%) 0.109
Abdominal pain 57 (46.3%) 60 (46.9%) 1.000
Metabolic acidosis 36 (18.0%) 16 (9.2%) 0.016
Hypoalbuminemia 35 (17.8%) 13 (7.5%) 0.005
AKI 167(83.9%) 134 (77.5%) 0.145
Need for dialysis 73 (36.5%) 51 (29.3%) 0.153
Penicillin G use 49 (32.0%) 52 (42.6%) 0.079
Death 25 (12.5%) 22 (12.6%) 1.000
The data are shown as the mean¡SD and range (minimum-maximum) or as numbers with percentages in parentheses. Significance, p,0.05. Student’s
t-test and Fisher’s exact test.
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diagnostic criteria. In the present study, mortality was not
associated with the presence of thrombocytopenia. Other
studies also showed that mortality was not associated with
the presence of thrombocytopenia (16,17), but Spichler et al.
(14) showed that it was associated with lethal outcomes,
being an independent risk factor for mortality in leptos-
pirosis.
Hemorrhagic manifestations are characteristic of Weil’s
disease and are potentially fatal. Patients can develop
important hemodynamic abnormalities secondary to hypo-
volemia, which is caused by dehydration and the direct
effects of Leptospira toxins that damage the vascular
endothelium and increase permeability (6). Hemorrhage is
recognized as the most important manifestation of human
leptospirosis and is being increasingly reported around the
world (24). The main hemorrhagic manifestations reported
in this study were epistaxis, hemoptysis, hematemesis and
hematuria, all of which were more frequent in the patients
in the thrombocytopenia group.
AKI in leptospirosis is reported in 40-60% of severe cases
(25) and is usually non-oliguric (26,27). However, the
present study found a higher prevalence (80.5%) according
to the RIFLE criteria. There were no differences between the
two groups regarding renal function or the need for dialysis.
This analysis found that lengthy disease and the presence
of AKI were associated with thrombocytopenia during the
hospital stay. Regarding antibiotic therapy in leptospirosis,
in the present study, penicillin G was administered to 152
(41.6%) of the patients, and there was a tendency toward
more frequent use of penicillin among those patients with
thrombocytopenia.
Thrombocytopenia in leptospirosis is known to be
associated with a worse prognosis (9). Tantitanawat and
Tanjatham (28) found that platelet counts ,100,000/mm3
were an independent risk factor for death in leptospirosis.
However, the present study found similar mortality rates in
patients with and without thrombocytopenia. A low DBP,
advanced age and oliguria were independent risk factors for
death.
In summary, leptospirosis is a globally relevant disease
with a potentially fatal outcome. Hemorrhagic complications
are common and are reported as main causes of morbidity
and mortality in this disease. Although thrombocytopenia
Table 2 - Comparison of laboratory data between leptospirosis patients with and without thrombocytopenia at
admission.
Thrombocytopenia No thrombocytopenia p-value
(N = 200) (N = 174)
Urea at admission (mg/dL) 134.9¡88.7 126.1¡94.7 0.169
(19-578) (15-449)
Creatinine at admission (mg/dL) 4.1¡2.8 4.2¡3.0 0.953
(0.3-15.2) (0.2-13.0)
Sodium at admission (mEq/L) 132.5¡6.5 133.8¡5.7 0.164
(114-158) (118-149)
Potassium at admission(mEq/L) 3.8¡0.9 4.0¡1.0 0.098
(2.0-8.2) (2.4-8.6)
Potassium min (mEq/L) 3.2¡0.6 3.5¡0.6 ,0.0001
(0.5-5.3) (2.0 – 4.8)
Creatine kinase at admission (UI/L) 976¡3032.1 252.2¡511 0.092
(3-19692.0) (12.0-1978)
Total bilirubin at admission (g/dL) 12.3¡11.0 7.5¡9.1 0.001
(0.6-49.5) (0.1-32.7)
Albumin at admission (g/dL) 2.9¡0.6 3.2¡0.6 0.067
(1.7-4.4) (2.0-4.3)
AST at admission (UI/L) 123¡106 149.8¡420 0.078
(23-604) (9-4215)
ALT at admission (UI/L) 77.2¡90.6 81.1¡85.1 0.871
(11-956) (8-734)
Hb at admission (g/dL) 10.7¡2.0 11.2¡2.1 0.021
(4.4-15.7) (6.8-11.2)
HCO3
- at admission (mEq/L) 18.8¡4.7 19.5¡5.3 0.375
(8.9-18.2) (9.0-20.2)
TAP (%) 74.6¡22.8 74.7¡18.9 0.284
(17.3-100) (35.5-100)
The data are shown as the mean¡ SD and range (minimum-maximum) or as numbers with percentages in parentheses. Significance, p,0.05. Student’s
t-test and Fisher’s exact test.
Table 3 - Independent risk factors for thrombocytopenia
in patients with leptospirosis at admission.
OR 95% CI p-value
Low potassium level 0.7 0.5-0.9 0.02
Dehydration 2.1 1.2-3.5 0.006
Metabolic acidosis 2.3 1.0-5.4 0.03
OR: odds ratio; 95% CI: 95% confidence interval. Multivariate analysis;
chi-square test. Significance, p,0.05.
Table 4 - Independent risk factors for thrombocytopenia
in patients with leptospirosis during their hospital stay.
OR 95% CI p-value
Lengthy disease 1.2 1.0-1.4 0.001
AKI 6.6 1.8-23 0.004
OR: odds ratio; 95% CI: 95% confidence interval. Multivariate analysis;
chi-square test. Significance, p,0.05.
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was associated with mortality in previous studies, in the
present study, this complication was not a risk factor for
death. Advanced age and oliguria were independent risk
factors for death.
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Table 5 - Independent risk factors for death in patients
with leptospirosis.
OR 95% CI p-value
Diastolic blood pressure 0.9 0.8-0.9 0.02
Advanced age 1.0 1.0-1.1 0.001
Oliguria 5.4 1.6-18 0.006
OR: odds ratio; 95% CI: 95% confidence interval. Multivariate analysis;
chi-square test. Significance, p,0.05.
Thrombocytopenia in leptospirosis
Daher EF et al.
CLINICS 2014;69(2):106-110
110
